Market Overview:
The global inhaled antibiotics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of respiratory tract infections, rising demand for targeted therapies, and technological advancements in inhalation devices. By type, the nebulized segment is expected to account for the largest share of the global market in 2018. This segment is also projected to grow at a higher CAGR than other segments during the forecast period. By application, ventilator-associated pneumonia (VAP) is expected to account for the largest share of the global market in 2018.
Product Definition:
Inhaled antibiotics are a type of medication that is used to treat infections in the lungs. They are often used when other treatments, such as oral antibiotics, have not been effective. Inhaled antibiotics can be very effective in treating lung infections and helping to improve breathing.
Nebulized:
Nebulized antibiotics are a type of antibiotic that is administered by inhalation. The drug takes effect in as little as 15 to 45 minutes and has a duration of 4-6 hours, which is much longer than the oral antibiotic drugs. Nebulized antibiotics can be used for the treatment of respiratory infections such as bronchitis, pneumonia, and asthma along with ear infections and sinusitis among others.
Dry Powder:
Dry powder is a free-flowing granular material that contains the active ingredients. It can be either inhaled as an aerosol or nebulized for pulmonary administration. The most commonly used dry powders are antibiotics, which are used to treat respiratory infections such as tuberculosis and pneumonia.
The global inhaled antibiotics market was valued at USD 2,708 million in 2016.
Application Insights:
In terms of revenue, the ventilator-associated pneumonia segment dominated the global inhalation antibiotics market in 2017 owing to high incidence rates and prevalence of diseases such as CAP. According to a study published in The Journal of Infectious Diseases, around 1 in 5 patients with CAP require mechanical ventilation during hospitalization. In addition, an increase in healthcare costs is expected to fuel the growth of this application segment over the forecast period.
The others application segment includes skin and soft tissue infections (SSTIs) and osteomyelitis. The rising number of SSTIs is one factor that may drive market growth over the forecast period as these infections are often treated with antibiotics due to their high bacterial count leading to increased demand for inhaled antibiotic drugs for treatment purposes.
Regional Analysis:
North America dominated the global inhaled antibiotics market in 2017. This is due to favorable reimbursement policies, increasing R&D investments by key players and rising healthcare expenditure in this region. In addition, a high prevalence of ventilator-associated pneumonia and other respiratory infections is also expected to drive the growth of this regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to factors such as improving economic conditions, growing medical tourism industry and an increase in healthcare expenditure by government & private sectors. Moreover, increasing incidence of hospital-acquired infections due to poor hygiene practices will also boost product demand during the forecast period.
Growth Factors:
- Increasing incidence of respiratory tract infections: The global incidence of respiratory tract infections is increasing due to the changing lifestyle and environmental conditions. This is expected to drive the demand for inhaled antibiotics in the coming years.
- Growing awareness about the benefits of inhaled antibiotics: There is a growing awareness among physicians and patients about the benefits of using inhaled antibiotics over oral or intravenous antibiotics. This is likely to boost demand for these drugs in the coming years.
- Technological advancements in inhalers: The development of novel inhalers that deliver drugs directly to the lungs has led to an increase in adoption rates of inhaled antibiotics globally. This is expected to propel market growth during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Inhaled Antibiotics Market Research Report
By Type
Nebulized, Dry Powder
By Application
Ventilator-associated Pneumonia, VAP, Ventilator-associated Tracheobronchitis, VAT, Others
By Companies
Lupin, Gilead Sciences, Inc, Savara Pharmaceuticals, Aradigm, Polyphor, Pharmaero, Pharmaxis Ltd, Insmed Incorporated, Joincare Pharmaceutical Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Inhaled Antibiotics Market Report Segments:
The global Inhaled Antibiotics market is segmented on the basis of:
Types
Nebulized, Dry Powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ventilator-associated Pneumonia, VAP, Ventilator-associated Tracheobronchitis, VAT, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lupin
- Gilead Sciences, Inc
- Savara Pharmaceuticals
- Aradigm
- Polyphor
- Pharmaero
- Pharmaxis Ltd
- Insmed Incorporated
- Joincare Pharmaceutical Group
Highlights of The Inhaled Antibiotics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nebulized
- Dry Powder
- By Application:
- Ventilator-associated Pneumonia, VAP
- Ventilator-associated Tracheobronchitis, VAT
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Inhaled Antibiotics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Inhaled antibiotics are medications that are inhaled through the nose. They are used to treat infections of the nose and throat. Inhaled antibiotics work by killing bacteria in the airways.
Some of the major companies in the inhaled antibiotics market are Lupin, Gilead Sciences, Inc, Savara Pharmaceuticals, Aradigm, Polyphor, Pharmaero, Pharmaxis Ltd, Insmed Incorporated, Joincare Pharmaceutical Group.
The inhaled antibiotics market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Inhaled Antibiotics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Inhaled Antibiotics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Inhaled Antibiotics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Inhaled Antibiotics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Inhaled Antibiotics Market Size & Forecast, 2020-2028
4.5.1 Inhaled Antibiotics Market Size and Y-o-Y Growth
4.5.2 Inhaled Antibiotics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Nebulized
5.2.2 Dry Powder
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Ventilator-associated Pneumonia
6.2.2 VAP
6.2.3 Ventilator-associated Tracheobronchitis
6.2.4 VAT
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Inhaled Antibiotics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Inhaled Antibiotics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Nebulized
9.6.2 Dry Powder
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Ventilator-associated Pneumonia
9.10.2 VAP
9.10.3 Ventilator-associated Tracheobronchitis
9.10.4 VAT
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Nebulized
10.6.2 Dry Powder
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Ventilator-associated Pneumonia
10.10.2 VAP
10.10.3 Ventilator-associated Tracheobronchitis
10.10.4 VAT
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Nebulized
11.6.2 Dry Powder
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Ventilator-associated Pneumonia
11.10.2 VAP
11.10.3 Ventilator-associated Tracheobronchitis
11.10.4 VAT
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Nebulized
12.6.2 Dry Powder
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Ventilator-associated Pneumonia
12.10.2 VAP
12.10.3 Ventilator-associated Tracheobronchitis
12.10.4 VAT
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Nebulized
13.6.2 Dry Powder
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Ventilator-associated Pneumonia
13.10.2 VAP
13.10.3 Ventilator-associated Tracheobronchitis
13.10.4 VAT
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Inhaled Antibiotics Market: Competitive Dashboard
14.2 Global Inhaled Antibiotics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Lupin
14.3.2 Gilead Sciences, Inc
14.3.3 Savara Pharmaceuticals
14.3.4 Aradigm
14.3.5 Polyphor
14.3.6 Pharmaero
14.3.7 Pharmaxis Ltd
14.3.8 Insmed Incorporated
14.3.9 Joincare Pharmaceutical Group
